|Articles|June 1, 2003
SCC, BCC Immunotherapy
San Francisco - Topical immunomodulators, specifically imiquimod 5 percent cream (Aldara), may be a viable option for treating patients with invasive squamous cell carcinoma (SCC) or aggressive basal cell carcinoma (BCC) who are no longer candidates for surgery, said Ulrich Hengge, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5














